Tropism

Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, April 1, 2024
Research, Glucose, Health, Congress, Obesity, Human, Drug discovery, Exercise, Glycated hemoglobin, DMR, ADAS, Partnership, Insulin, IDA, Patient, Weight loss, Michigan Medicine, Diabetes, Public expenditure, IDE, University, IPO, Tropism, Peptide, Transgene, Insulin resistance, Animal, NUB, Type 2 diabetes, Pancreas, Investigational New Drug, Therapy, Food, Marketing, FDA, Engineering, Annual general meeting, Pharmaceutical industry

BURLINGTON, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.

Key Points: 
  • “In addition, we expect to complete enrollment of our pivotal Revitalize-1 study and are excited to report topline data in the fourth quarter of 2024.
  • The Company expects to complete enrollment in the first half of 2024 and report topline data in the fourth quarter of 2024.
  • In December 2023, Fractyl presented preclinical findings in an oral presentation at the World Congress of Insulin Resistance Diabetes and Cardiovascular Disease 2023 Annual Meeting.
  • Cash Position: As of December 31, 2023, Fractyl had approximately $33.2 million in cash and cash equivalents.

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
Tuesday, March 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

Retrieved on: 
Wednesday, March 13, 2024
Research, Neurology, Genetics, Clinical Trials, Health, Pharmaceutical, General Health, Other Science, Science, STAC, AAV, Sangamo Therapeutics, Gene, Brain, Capsid, Gene expression, ALS, BBB, Central nervous system, Novartis, CNS, CTA, DRG, Traffic barrier, Prion, NHP, Tropism, IND, Nav1.7, Neuron, Biogen, Tauopathy, Excipient, Therapy, DSM-IV codes, Spinal cord, Liver, Animal, Vaccine

Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.

Key Points: 
  • Sangamo is exploring avenues to resume development of these programs internally, subject to receipt of adequate funding, or with new potential collaborators.
  • In NHP studies when administered intravenously at clinically relevant doses, STAC-BBB demonstrated its potential to be a leading neurotropic capsid.
  • Exhibited 700-fold higher transgene expression in neurons compared to the benchmark capsid AAV9 and outperformed all other known published neurotropic capsid variants evaluated in the study.
  • STAC-BBB was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues.

Therapeutic mRNA Patent Monitoring Service 2024: Track Competitors' IP Activities and their Future Intentions

Retrieved on: 
Tuesday, April 2, 2024
PDF, Q&A, COVID-19, DSM-IV codes, Knowledge, RNA, Messenger, Tropism, IP, Cancer, Vaccination, Invention, Pharmacokinetics, Patent, Microsoft Excel, Therapy, Vaccine, Orientation, Directory

The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.

Key Points: 
  • The directory includes new patent applications, new granted patents, patents expired/abandoned, patent transfers (re-assignment, licensing), and patent litigation/opposition.
  • The success of mRNA vaccines as a response to the COVID-19 pandemic has shone a light on the disruptive aspect of mRNA-based therapeutic technology.
  • With the help of the patent monitoring service, you will be aware of your competitors' current patenting activities, their IP dynamics, patent transfers including acquisitions and licenses, patent litigation, technology development, and R&D strategies.
  • Main patent applicants and their inventions, blocking patents, promising patents, and key newly expired or abandoned patents will be highlighted
    Featured image of Therapeutic mRNA patent monitor.

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, Telephone, Initiate, Myositis, Tumor microenvironment, Risk, Probability, IND, Autoimmunity, FDA, Cytokine release syndrome, CD20, Renal cell carcinoma, Scleroderma, Tissue, Cmax, Cancer, TGF, Tropism, NHL, Patient, CD19, AUC, Safety, Lupus nephritis, CD70, MCL, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and highlighted upcoming priorities for its pipeline programs in 2024.
  • “In 2024, we aim to make significant strides across our pipeline of differentiated gamma delta T cell therapies through our strategic and disciplined approach,” said Chen Schor, President and Chief Executive Officer at Adicet Bio.
  • Initiate Phase 1 clinical trial of ADI-001 for the treatment of lupus nephritis in the second quarter of 2024.
  • The Company remains on track to provide an ADI-001 clinical update in the second half of 2024.

Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Genetics, Health, SCGE, RNA, Gene editing, Cell, Therapy, Tropism, Genome, Bangladesh Technical Education Board, NIH, Vaccine

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge .

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge .
  • The Company’s proposal, “Engineered ARMMs: Promising Human-Derived Vectors for Cell Type-Specific Delivery of Genome Editors”, builds on recent data demonstrating directed tropism of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) delivery platform and was among five proposals selected as “Winning Solutions” for programmable delivery systems for gene editing.
  • We look forward to advancing our platform toward the clinic and unlocking the full potential of genetic medicines.”
    The NIH launched the TARGETED Challenge to advance genome editing technology by sourcing innovative solutions for delivering genome editing components safely and effectively.
  • The three-phase challenge supports the NIH's Somatic Cell Genome Editing (SCGE) commitment to developing targeted delivery systems for delivering genome editors to somatic cells in the body.

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Wednesday, November 8, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CAR, Trial of the century, IND, Food, Bio, CD70, Renal cell carcinoma, International Conference on Afghanistan, London (2010), CD20, Society for Immunotherapy of Cancer, Tropism, TGF, Conference, CDMO, Regulation of tobacco by the U.S. Food and Drug Administration, Prostate cancer, R, Engineering, Poster, Goodwill, SITC, Immunotherapy, MCL, Research and development, Annual general meeting, Probability, ACET, Tumor microenvironment, Epitope, NHL, Society, Cancer, PSMA, Patient, Administration, Prognosis, Prostate, CD27, Pharmaceutical industry, Cryptocurrency

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today reported financial results and operational highlights for the third quarter ended September 30, 2023.
  • In October 2023, Adicet presented new preclinical data building on the potential of Adicet’s allogeneic gamma delta platform as a promising approach to target prostate cancer.
  • Financial Results for Third Quarter 2023:
    Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the three months ended September 30, 2023, compared to $16.6 million during the same period in 2022.
  • Cash Position: Cash and cash equivalents were $183.3 million as of September 30, 2023, compared to $257.7 million as of December 31, 2022.

Ring Therapeutics Presents New Data on Anellogy™ Platform at the 30th Annual European Society of Gene & Cell Therapy Congress

Retrieved on: 
Tuesday, October 24, 2023
RNA, Tropism, Flagship Pioneering, Transduction, MD, MBA, Tissue, Cell, Gene, ESGCT, European Society of Gene and Cell Therapy, Genome, Therapy, DNA, Vaccine

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced new preclinical data demonstrating a functional anellovirus-based viral vector and the innovative manufacturing technology enabling its production at scale. The data, which will be presented in two posters at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), validates the Anellogy platform’s potential to overcome some of the largest barriers facing gene therapy today.

Key Points: 
  • The data, which will be presented in two posters at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), validates the Anellogy platform’s potential to overcome some of the largest barriers facing gene therapy today.
  • "I am extremely proud of the team at Ring as we reach this critical milestone showcasing Anellovectors as a viable viral vector for genetic medicines,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring Therapeutics and CEO-Partner at Flagship Pioneering.
  • “Building on the foundational work characterizing anelloviruses, we have achieved in vivo transduction of Anellovectors, supported by our modular AnelloBricks manufacturing technology, to produce them at scale.
  • DNA, RNA)
    AnelloBricks offers payload versatility while reducing manufacturing complexity, resulting in a readily scalable production system

Vesigen Highlights Data Demonstrating Directed Tropism of Non-Viral Delivery Platform at the 30th Annual Congress of the European Society of Gene & Cell Therapy

Retrieved on: 
Wednesday, October 25, 2023
Biotechnology, Health, Genetics, Science, Research, Gene editing, Delivery, RNA, Tropism, ARMM, Macrophage, Liver, ARMM Regional Legislative Assembly, Mouse, Cell, Gene, ESGCT, European Society of Gene and Cell Therapy, Genome, Biodistribution, Therapy, Vaccine

Data highlighted the first demonstration of cell type-specific targeting of ARMMs and functional delivery of base editing complexes across diverse human cell types.

Key Points: 
  • Data highlighted the first demonstration of cell type-specific targeting of ARMMs and functional delivery of base editing complexes across diverse human cell types.
  • The data were presented at the 30th Annual Congress of the European Society of Cell and Gene Therapy (ESGCT), taking place October 24-27 in Brussels, Belgium.
  • “The data we presented at ESGCT represent the first demonstration of directed tropism of our non-viral ARMMs delivery platform.
  • This important result expands upon the natural biodistribution of ARMMs and demonstrates that ARMMs can be engineered to selectively target cell types of interest,” said Paulash Mohsen, Chief Executive Officer at Vesigen.

American Lung Association Funds $13.6 Million in Research for a Future Free of Lung Disease

Retrieved on: 
Thursday, October 12, 2023
Havasupai Tribe v. the Arizona Board of Regents, Manning Innovation Awards, T helper cell, Immunotherapy, COVID-19, Omicron, Lung cancer, Tropism, Icahn School of Medicine at Mount Sinai, Asthma, University of Arizona, Natural killer T cell, Research, COPD, Boston University, Immunoglobulin E, University, Disease, Lung, Patient, Award, American Lung Association, CHI3L1, Canadian Lung Association, Immunology, Helminthiasis, Trustee, Research institute, Infection, SARS-CoV-2, RSV, TFH, Blood, Mount Sinai, Pharmaceutical industry, Vaccine, School

CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow. Lung research is critical because one in 10 people in the U.S. are living with a lung disease and each year, millions of people are impacted by respiratory viruses like COVID-19 and influenza.

Key Points: 
  • Organization funds 129 promising research grants on lung cancer, asthma, COVID-19 and more
    CHICAGO, Oct. 12, 2023 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it awarded $13.6 million in research grants to fund 129 innovative projects to advance today's science to end the burden of lung disease tomorrow.
  • Through the Awards and Grants Program, the Lung Association supports trailblazing research, novel ideas and innovative approaches.
  • The Lung Association's Awards and Grants Program promotes innovative research, collaboration, translation of discoveries and scientific exchange to transform today's science into tomorrow's solutions," said Harold Wimmer, President and CEO of the American Lung Association.
  • For more information about the new grant awardees and the entire American Lung Association research team, visit Lung.org/research-team .